Comparison Overview

Alembic Pharmaceuticals Limited

VS

Merck

Alembic Pharmaceuticals Limited

Alembic Road, Vadodara, 390003, IN
Last Update: 2025-12-09
View Profile
Between 750 and 799
http://www.alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,958
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Merck

126 E Lincoln Ave, P.O. Box 2000, Rahway, New Jersey, US, 07065
Last Update: 2025-12-09
Between 800 and 849
http://merck.us/2J2xAUh

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 42,297
Subsidiaries: 2
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/merck.jpeg
Merck
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Alembic Pharmaceuticals Limited
100%
Compliance Rate
0/4 Standards Verified
Merck
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alembic Pharmaceuticals Limited in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

Merck has 25.0% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — Alembic Pharmaceuticals Limited (X = Date, Y = Severity)

Alembic Pharmaceuticals Limited cyber incidents detection timeline including parent company and subsidiaries

Incident History — Merck (X = Date, Y = Severity)

Merck cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
Incidents

No Incident

https://images.rankiteo.com/companyimages/merck.jpeg
Merck
Incidents

Date Detected: 9/2025
Type:Breach
Blog: Blog

Date Detected: 06/2017
Type:Cyber Attack
Blog: Blog

FAQ

Merck company demonstrates a stronger AI Cybersecurity Score compared to Alembic Pharmaceuticals Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Merck company has historically faced a number of disclosed cyber incidents, whereas Alembic Pharmaceuticals Limited company has not reported any.

In the current year, Merck company has reported more cyber incidents than Alembic Pharmaceuticals Limited company.

Neither Merck company nor Alembic Pharmaceuticals Limited company has reported experiencing a ransomware attack publicly.

Merck company has disclosed at least one data breach, while Alembic Pharmaceuticals Limited company has not reported such incidents publicly.

Merck company has reported targeted cyberattacks, while Alembic Pharmaceuticals Limited company has not reported such incidents publicly.

Neither Alembic Pharmaceuticals Limited company nor Merck company has reported experiencing or disclosing vulnerabilities publicly.

Neither Alembic Pharmaceuticals Limited nor Merck holds any compliance certifications.

Neither company holds any compliance certifications.

Merck company has more subsidiaries worldwide compared to Alembic Pharmaceuticals Limited company.

Merck company employs more people globally than Alembic Pharmaceuticals Limited company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Alembic Pharmaceuticals Limited nor Merck holds SOC 2 Type 1 certification.

Neither Alembic Pharmaceuticals Limited nor Merck holds SOC 2 Type 2 certification.

Neither Alembic Pharmaceuticals Limited nor Merck holds ISO 27001 certification.

Neither Alembic Pharmaceuticals Limited nor Merck holds PCI DSS certification.

Neither Alembic Pharmaceuticals Limited nor Merck holds HIPAA certification.

Neither Alembic Pharmaceuticals Limited nor Merck holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References